Tuesday, December 06, 2011 12:22:25 PM
Roche Acquires Verum Diagnostica GmbH as Part of Plan to Develop Comprehensive Coagulation Testing Portfolio for Diagnostic L...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market.
The acquisition supports plans Roche announced in October to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of coagulation analyzers for hospital and reference laboratories. The new line is expected to be introduced in the U.S. and Canada in 2014, subject to regulatory approval and other requirements.
"Improving the assessment of a patient's platelet function status is currently a significant unmet need for hematologists, cardiologists and anesthetists in order to support clinical decisions in cardiology, surgery and intensive care," said Colin Brown, Head of Roche Professional Diagnostics. "With this acquisition we gain an innovative and unique platelet function testing solution which has the potential to set new standards of patient care in this area and perfectly complements our new coagulation portfolio." Coagulation diagnostics has become an important area in clinical diagnostics and Roche has already begun to make significant investments in this field.
Under the terms of the acquisition agreement, Roche will pay Verum Diagnostica shareholders a total cash consideration of eleven million euros, and potentially a further two million euros contingent upon reaching certain performance-related milestones. The transaction is subject to customary closing conditions and is expected to close in January 2012.
Laboratory coagulation is estimated to be the fifth-largest market in professional diagnostics worldwide, representing approximately 1.3 billion USD in sales in 2010 and having a projected annual growth rate of 5.1% over the next five years. Platelet function testing represents an unmet medical need and has the potential to expand the available market significantly.
About Verum Diagnostica
Verum Diagnostica GmbH is a 100 percent subsidiary of Dynabyte Informationssysteme GmbH, developing, producing and marketing the Multiplate analyzer, test cells and reagents for the determination of platelet function in whole blood for use in hospital laboratories and near-patient settings, such as interventional cardiology, surgery and intensive care. Operating globally in more than 45 countries, the company is based in the biotech cluster and academic center of Munich, Germany, and closely cooperates with an extensive network of clinical partners. Verum Diagnostica will become part of Roche's Professional Diagnostics business area.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.
All trademarks mentioned in this release are protected by law.
For further information, please contact:
Betsy Cox
Melanie Lussier
Director, Corporate Communications
Associate Manager, Communications
Roche Diagnostics Corporation
Roche Diagnostics Canada
Indianapolis, Indiana USA
Laval, Quebec, Canada
(317) 521-3911
(450) 686-3137
betsy.cox@roche.com
melanie.lussier@roche.com
SOURCE Roche Diagnostics
Recent RHHBY News
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Roche's Cancer Injection Tecentriq SC Gets European Commission Approval • Dow Jones News • 01/16/2024 06:49:00 AM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche • Dow Jones News • 12/29/2023 10:07:00 PM
- Roche's Xolair Granted FDA Priority Review • Dow Jones News • 12/19/2023 03:27:00 PM
- Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment • Dow Jones News • 12/11/2023 03:31:00 PM
- Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment • Dow Jones News • 12/08/2023 05:56:00 PM
- Roche's Inavolisib Breast Cancer Drug Gets Positive Results • Dow Jones News • 12/08/2023 05:38:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study • Dow Jones News • 12/05/2023 06:54:00 AM
- Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion • Dow Jones News • 12/04/2023 03:12:00 PM
- Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update • Dow Jones News • 12/04/2023 11:34:00 AM
- Alaska Air Acquires Hawaiian Holdings, Spotify Cuts 1,500 Jobs, Uber’s S&P 500 Entry, and More • IH Market News • 12/04/2023 10:55:07 AM
- Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Billion • Dow Jones News • 12/04/2023 06:47:00 AM
- Roche's Genentech, Nvidia Team Up to Accelerate Drug Discovery With AI • Dow Jones News • 11/21/2023 04:06:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2023 10:14:35 PM
- Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal • Dow Jones News • 10/31/2023 06:26:00 AM
- Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment • Dow Jones News • 10/27/2023 05:40:00 AM
- Trending: Roche to Buy Telavant From Roivant and Pfizer • Dow Jones News • 10/23/2023 07:41:00 PM
- Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update • Dow Jones News • 10/23/2023 08:16:00 AM
- Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal • Dow Jones News • 10/23/2023 05:50:00 AM
- Roche Shares Fall on Lower Sales Due to Currency Hit • Dow Jones News • 10/19/2023 09:55:00 AM
- Roche Backs Guidance After Sales Fall • Dow Jones News • 10/19/2023 05:48:00 AM
- Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial • Dow Jones News • 10/18/2023 06:14:00 AM
- Roche's Elecsys IL-6 Test Approved for Diagnosis of Neonatal Sepsis • Dow Jones News • 10/18/2023 05:54:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM